Subcutaneous Ig NextGen 16% in PID Patients
NCT00391131
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
35
Enrollment
INDUSTRY
Sponsor class
Conditions
Primary Immunodeficiency (PID)
Interventions
DRUG:
IgNextGen 16%
Sponsor
CSL Limited